Snu S Spacemetadata only
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial
pembrolizumab plus chemotherapy, antibody-drug conjugate, double-blind, ds-8201a
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 428717
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.